Recursion director granted 88,424 RSUs

HERSHBERG ROBERT reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

HERSHBERG ROBERT reported acquisition or exercise transactions in this Form 4 filing.

RECURSION PHARMACEUTICALS, INC. director Robert Hershberg received an equity grant of 88,424 shares of Class A Common Stock in the form of restricted stock units. The grant was made at no cash cost under the company’s Outside Director Compensation Policy as a routine award.

These restricted stock units vest on the earlier of June 17, 2027 or the day before the company’s 2027 annual stockholder meeting, contingent on his continued service. Following this grant, Hershberg directly holds 162,156 shares reported as beneficially owned.

Insider Trade Summary

Grant/Award: 88,424 shares

Grant/Award 1 txn

Insider HERSHBERG ROBERT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	88,424	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 162,156 shares (Direct)

Footnotes (1)

1. F1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Key Figures

RSU grant size: 88,424 shares Grant price per share: $0.0000 per share Post-grant holdings: 162,156 shares +1 more

4 metrics

RSU grant size 88,424 shares Restricted stock units granted to director on June 17, 2026

Grant price per share $0.0000 per share Equity award made at no cash cost

Post-grant holdings 162,156 shares Total Class A Common Stock beneficially owned after transaction

Vesting trigger date June 17, 2027 RSUs vest on earlier of this date or day prior to 2027 annual meeting

Key Terms

restricted stock units, Outside Director Compensation Policy, beneficially owned, Grant, award, or other acquisition

4 terms

restricted stock units financial

"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Outside Director Compensation Policy financial

"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy."

beneficially owned financial

"total_shares_following_transaction: 162156.0000"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RXRX director Robert Hershberg report on this Form 4?

Robert Hershberg reported receiving 88,424 restricted stock units of Recursion Class A Common Stock as a routine equity grant. The grant was made at no cash cost under the Outside Director Compensation Policy and represents compensation, not an open-market stock purchase or sale.

How many RXRX shares does Robert Hershberg hold after this grant?

After the reported grant, Robert Hershberg beneficially owns 162,156 shares of Recursion Class A Common Stock. This total reflects his direct holdings following the award of 88,424 restricted stock units disclosed in the filing and shows his overall reported equity stake as a director.

When do Robert Hershberg’s new RXRX restricted stock units vest?

The 88,424 restricted stock units vest on the earlier of June 17, 2027 or the day before Recursion’s 2027 annual stockholder meeting. Vesting is contingent on Hershberg’s continued service to the company, aligning the award with ongoing board participation and governance responsibilities.

Was cash paid for the RXRX shares reported in this Form 4?

No cash was paid for these shares; the Form 4 shows a price per share of 0.0000. The 88,424 units were granted as equity compensation under Recursion’s Outside Director Compensation Policy, rather than through an open-market purchase or other cash transaction.

Is this RXRX Form 4 an open-market insider buy or sale?

This Form 4 does not show an open-market buy or sale. It reports a grant of 88,424 restricted stock units as compensation, coded as a grant or award acquisition, which is a routine non-market transaction for a board member under the company’s director compensation program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HERSHBERG ROBERT

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/17/2026		A(1)		88,424	A	$0	162,156	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)